These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 12 Suppl 1():S1-22. PubMed ID: 8680897 [No Abstract] [Full Text] [Related]
88. [Acyclovir and ganciclovir in the treatment of malignant hematological diseases]. Zhou X; Gan X; Meng P Zhonghua Nei Ke Za Zhi; 1997 May; 36(5):349-51. PubMed ID: 10374276 [No Abstract] [Full Text] [Related]
89. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Kern ER Transplant Proc; 1991 Jun; 23(3 Suppl 3):152-5, discussion 155. PubMed ID: 1648821 [No Abstract] [Full Text] [Related]
90. [Gastrointestinal cytomegalovirus infections in organ transplant patients]. Péter A; Telkes G; Varga M; Járay J Orv Hetil; 2008 Dec; 149(52):2463-70. PubMed ID: 19087914 [TBL] [Abstract][Full Text] [Related]
91. [Valganciclovir. Oral treatment of Cytomegalovirus infections]. Kroes AC Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386 [TBL] [Abstract][Full Text] [Related]
92. Herpes simplex virus drug-resistance: new mutations and insights. Andrei G; Snoeck R Curr Opin Infect Dis; 2013 Dec; 26(6):551-60. PubMed ID: 24152761 [TBL] [Abstract][Full Text] [Related]